Alembic Pharmaceuticals Reports Mixed Financial Results Amidst Growth and Rising Costs in March 2025
Alembic Pharmaceuticals has reported its financial results for the quarter ending March 2025, showcasing record quarterly net sales of Rs 1,769.64 crore and the highest operating profit in five quarters at Rs 271.93 crore. However, challenges include a decline in profit after tax and increased interest expenses.
Alembic Pharmaceuticals has recently reported its financial results for the quarter ending March 2025, revealing a complex picture of performance within the midcap pharmaceuticals and drugs industry. The company's score has undergone an adjustment, moving to -7 from -14 over the past three months, indicating a shift in evaluation.On a positive note, Alembic Pharma achieved its highest quarterly net sales at Rs 1,769.64 crore, marking consistent growth over the last five quarters. Additionally, the operating profit (PBDIT) reached Rs 271.93 crore, also the highest in the same timeframe, suggesting a favorable near-term trend in operating profitability.
Conversely, the company faces challenges as well. The operating profit to interest ratio has reached its lowest point at 11.09 times, reflecting a decline in the company's capacity to manage interest payments effectively. Furthermore, profit after tax (PAT) has seen a year-on-year decrease of 12.0%, indicating a negative trend in profitability. The interest expense has also risen to Rs 24.52 crore, the highest in five quarters, highlighting increased borrowing costs.
Overall, Alembic Pharmaceuticals' recent financial results present a mixed landscape of growth and challenges that warrant close attention.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
